Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)

Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.

Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.

Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.

Supplementary Fig. 4. Naive T cells associated with improved outcome.

Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.

Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.

Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.

Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.

Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.

Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.

Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.

Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.

Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.

Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.

Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.

Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.